Dermatomyositis Treatment Global Market Report 2025

The dermatomyositis treatment market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.91 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historical period is attributed to the rising prevalence of autoimmune diseases, increased awareness of rare inflammatory conditions, global growth in healthcare expenditure, higher diagnosis rates resulting from enhanced screening methods, and growing demand for effective alternatives to corticosteroids.

The dermatomyositis treatment market size is expected to see strong growth in the next few years. It will grow to $1.2 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The projected growth during the forecast period is driven by increasing investments in autoimmune disease research, a rise in clinical trials for new biologic therapies, greater adoption of targeted immunosuppressants, expanding collaborations among biotech companies, and growing demand for personalized treatment options. Key trends expected in the forecast period include progress in targeted immunotherapies, expanded use of mRNA-based therapies, development of new JAK inhibitors, innovations in biologics targeting interferon pathways, and advancements in personalized treatment strategies.

The rising prevalence of autoimmune diseases is anticipated to drive the growth of the dermatomyositis treatment market in the future. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues. This increase in autoimmune conditions is fueled by advancements in diagnostic methods, growing awareness, and environmental factors, which contribute to higher detection rates and more reported cases. Treatments for dermatomyositis help manage this growing prevalence by providing targeted therapies that suppress harmful immune responses and enhance patients’ quality of life. For example, in February 2024, the Autoimmune Institute, a US-based nonprofit organization, reported that autoimmune diseases affect 5-10% of the population in industrialized countries. As a result, the rising prevalence of autoimmune diseases is propelling the expansion of the dermatomyositis treatment market.

Leading companies in the dermatomyositis treatment market are concentrating on developing innovative therapies, such as JAK inhibitors, to better manage inflammation by targeting specific enzymes involved in immune system overactivity. JAK inhibitors are drugs that block Janus kinase enzymes, helping to decrease the abnormal immune responses responsible for symptoms in autoimmune disorders. For example, in June 2022, Pfizer, a US-based pharmaceutical firm, introduced Brepocitinib, an oral JAK1 and TYK2 inhibitor aimed at reducing inflammation and muscle weakness in dermatomyositis patients. This oral form offers a more convenient option compared to traditional injectable therapies. Brepocitinib addresses the root causes of the disease and has demonstrated potential in enhancing patients’ quality of life.

In April 2025, Syneron Bio, a biotechnology firm based in China, partnered with AstraZeneca to jointly develop and commercialize innovative oral peptide therapies targeting chronic and autoimmune diseases. This collaboration combines Syneron Bio’s proprietary macrocyclic peptide technology with AstraZeneca’s global expertise in drug development. AstraZeneca, headquartered in the UK, is a pharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory conditions.

Major players in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., and Corbus Pharmaceuticals Holdings Inc.

North America was the largest region in the dermatomyositis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatomycosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dermatomycosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Treatment of dermatomycosis involves antifungal therapies designed to eradicate fungal skin infections. This usually includes the use of topical antifungal creams or ointments like clotrimazole, miconazole, or terbinafine for mild to moderate cases. In more severe or stubborn infections, oral antifungal drugs such as fluconazole or itraconazole may be recommended.

The primary treatment methods for dermatomyositis consist of pharmacological therapies, immunosuppressants, corticosteroids, biologics, and physical therapy. Pharmacological treatments involve the use of medications to manage, relieve, or address symptoms and root causes of the disease. These medications can be administered orally, intravenously, or subcutaneously, with patient groups categorized by age and gender. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, home care providers, specialty clinics, and other users.

The dermatomyositis treatment market research report is one of a series of new reports that provides dermatomyositis treatment market statistics, including the dermatomyositis treatment industry global market size, regional shares, competitors with the dermatomyositis treatment market share, detailed dermatomyositis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatomyositis treatment industry. This dermatomyositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dermatomycosis treatment market consists of revenues earned by entities by providing services such as natural and herbal remedies, antifungal shampoos, and immune-modulating treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The dermatomycosis treatment market also includes sales of antifungal nail lacquers, oral suspensions, and pediatric formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.